View Older Stories

May 13, 2026 08:05AM Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 6, 2026 08:10AM Aptevo reports 87% clinical benefit rate in frontline AML trial

May 6, 2026 08:05AM Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D

Mar 26, 2026 08:05AM Aptevo Provides State of the Business Report and 2025 Financial Results

Mar 19, 2026 08:05AM Aptevo to Participate in March 2026 Conferences

Mar 10, 2026 08:21AM Aptevo reports 86% clinical benefit rate for AML drug mipletamig

Mar 10, 2026 08:05AM Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Feb 3, 2026 08:06AM Aptevo Therapeutics announces CEO transition effective April

Feb 3, 2026 08:05AM Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Jan 28, 2026 04:23PM Aptevo Therapeutics (APVO) files for 7.08M share offering by selling stockholders

Jan 9, 2026 08:05AM Aptevo Therapeutics secures $60 million equity line of credit

Jan 9, 2026 08:05AM Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Dec 26, 2025 08:05AM Aptevo Therapeutics announces 1-for-18 reverse stock split

Dec 26, 2025 08:05AM Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 9, 2025 08:07AM Aptevo reports no cytokine release syndrome in AML drug trial

Dec 9, 2025 08:05AM Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Nov 10, 2025 08:05AM Aptevo presents preclinical data for trispecific antibody APVO451

Nov 10, 2025 08:05AM Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 6, 2025 08:05AM Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Oct 8, 2025 08:20AM Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Oct 1, 2025 04:34PM Aptevo Therapeutics (APVO) files for 6.9M share offering by selling stockholders

Sep 16, 2025 08:34AM Aptevo reports 100% remission rate in AML trial cohort 3

Sep 16, 2025 08:30AM Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 5, 2025 09:00AM Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 4, 2025 08:46AM Aptevo expands cancer pipeline with two trispecific drug candidates

Sep 4, 2025 08:45AM Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025 08:06AM Aptevo highlights preclinical prostate cancer therapy candidate

Aug 13, 2025 08:05AM Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025 10:53AM Aptevo Therapeutics (APVO) Misses Q2 EPS by 840c

Aug 11, 2025 08:05AM Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 8, 2025 09:00AM Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 25, 2025 04:18PM Aptevo Therapeutics (APVO) Files for 8.25M Share Offering by Selling Stockholders

Jun 20, 2025 11:30AM Aptevo Therapeutics (APVO) Announces Closing of $8 Million Offering

Jun 20, 2025 11:30AM Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025 08:55AM Aptevo Therapeutics (APVO) Expands Differentiated CD3 Portfolio with APVO455

Jun 20, 2025 08:55AM Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 18, 2025 10:53AM Aptevo Therapeutics (APVO) Halted on Volatility, Off Highs Following Offering

Jun 18, 2025 10:52AM Aptevo Therapeutics (APVO) Announces $8 Million Offering Priced At-the-Market

Jun 18, 2025 10:52AM Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025 08:07AM Aptevo Therapeutics (APVO): Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025 08:01AM Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025 08:05AM Aptevo Participating in the BIO International Convention

May 22, 2025 08:11AM Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025 08:05AM Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025 08:07AM Aptevo Therapeutics (APVO) Reports Q1, Provides an Update on Mipletamig

May 14, 2025 08:06PM Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025 08:45AM Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025 04:05PM Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025 02:42PM Aptevo Therapeutics (APVO) Announces 2.32M Share Offering at $0.862/sh

Apr 21, 2025 02:40PM Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

View Older Stories